JP2013525337A - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
JP2013525337A
JP2013525337A JP2013505533A JP2013505533A JP2013525337A JP 2013525337 A JP2013525337 A JP 2013525337A JP 2013505533 A JP2013505533 A JP 2013505533A JP 2013505533 A JP2013505533 A JP 2013505533A JP 2013525337 A JP2013525337 A JP 2013525337A
Authority
JP
Japan
Prior art keywords
sodium
particles
efavirenz
polymer
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013505533A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525337A5 (enExample
Inventor
ルルラ アマル
マルホトラ ゲエナ
Original Assignee
シプラ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シプラ・リミテッド filed Critical シプラ・リミテッド
Publication of JP2013525337A publication Critical patent/JP2013525337A/ja
Publication of JP2013525337A5 publication Critical patent/JP2013525337A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013505533A 2010-04-20 2011-04-20 医薬組成物 Pending JP2013525337A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1296/MUM/2010 2010-04-20
IN1296MU2010 2010-04-20
PCT/GB2011/000620 WO2011131943A2 (en) 2010-04-20 2011-04-20 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JP2013525337A true JP2013525337A (ja) 2013-06-20
JP2013525337A5 JP2013525337A5 (enExample) 2014-06-05

Family

ID=44625957

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013505533A Pending JP2013525337A (ja) 2010-04-20 2011-04-20 医薬組成物

Country Status (13)

Country Link
US (1) US20130302415A1 (enExample)
EP (1) EP2560617A2 (enExample)
JP (1) JP2013525337A (enExample)
KR (1) KR20130076818A (enExample)
CN (1) CN102985072A (enExample)
AU (1) AU2011244783B2 (enExample)
BR (1) BR112012026843A2 (enExample)
CA (1) CA2796494A1 (enExample)
GT (1) GT201200284A (enExample)
NZ (1) NZ602955A (enExample)
RU (1) RU2012149115A (enExample)
WO (1) WO2011131943A2 (enExample)
ZA (1) ZA201207670B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018532769A (ja) * 2015-08-28 2018-11-08 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ウロリチン化合物を含む組成物
JP2018533618A (ja) * 2015-08-28 2018-11-15 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ウロリチン化合物を含む組成物
JP2023505128A (ja) * 2019-12-02 2023-02-08 アストラゼネカ・アクチエボラーグ ６－（２－クロロ－６－メチルピリジン－４－イル）－５－（４－フルオロフェニル）－１，２，４－トリアジン－３－アミンの固形製剤処方物
JP2024038209A (ja) * 2020-04-20 2024-03-19 ポビバ コーポレーション 抗ウイルス薬剤の向上した送達の為の組成物及び方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115633D0 (en) * 2011-09-09 2011-10-26 Univ Liverpool Compositions of efavirenz
US10646452B2 (en) * 2013-03-15 2020-05-12 New Jersey Institute Of Technology System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process
IN2013MU03370A (enExample) 2013-10-25 2015-09-25 Cipla Ltd
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015140569A1 (en) * 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
CN104224790A (zh) * 2014-09-28 2014-12-24 苏州普罗达生物科技有限公司 一种依法韦仑组合物及其制备方法
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
AU2017364077A1 (en) 2016-11-22 2019-06-20 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
WO2019023392A1 (en) 2017-07-25 2019-01-31 Elektrofi, Inc. FORMATION OF PARTICLES COMPRISING AGENTS
US20230040901A1 (en) * 2018-01-04 2023-02-09 PlantTec Medical GmbH Pharmaceutical composition for inhibiting postoperative adhesions
ES2732498B2 (es) * 2018-05-21 2020-04-27 Consejo Superior Investigacion Uso de efavirenz para el tratamiento de enfermedades de almacenamiento lipidico.
WO2019226969A1 (en) 2018-05-24 2019-11-28 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
CN112236141A (zh) * 2018-06-11 2021-01-15 大塚制药株式会社 包含德拉马尼的组合物
AU2020214626B2 (en) 2019-01-31 2025-10-16 Halozyme Hypercon, Inc. Particle formation and morphology
AU2020344675B2 (en) 2019-09-13 2026-06-25 Halozyme Hypercon, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
US12377050B2 (en) 2020-04-17 2025-08-05 Elektrofi, Inc. Methods of forming particles by continuous droplet formation and dehydration
CN112245400B (zh) * 2020-11-10 2023-01-20 蓝龙药业(北京)有限公司 一种依法韦仑微片剂、制备方法及其应用
CN114404377B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008126797A1 (ja) * 2007-04-06 2008-10-23 Activus Pharma Co., Ltd. 微粉砕化有機化合物粒子の製造方法
WO2009026257A2 (en) * 2007-08-17 2009-02-26 Teva Pharmaceutical Industries Ltd. Methods and compositions for controlling the bioavailability of poorly soluble drugs
JP2009046438A (ja) * 2007-08-21 2009-03-05 Api Co Ltd アントシアニン含有組成物及びその製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
PE20000559A1 (es) 1998-05-27 2000-07-05 Merck & Co Inc Formulacion de tabletas comprimidas de efavirenz
AU2002359518A1 (en) * 2001-11-27 2003-06-10 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
US20070003623A1 (en) * 2005-06-29 2007-01-04 Wyeth Formulations of conjugated estrogens and bazedoxifene
US20080026062A1 (en) * 2006-07-31 2008-01-31 Isaac Farr Pharmaceutical compositions including nano-sized active agent
WO2010068899A1 (en) * 2008-12-12 2010-06-17 Creighton University Nanoparticles comprising combinations of antiretroviral agents and use thereof
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
GB201006038D0 (en) * 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008126797A1 (ja) * 2007-04-06 2008-10-23 Activus Pharma Co., Ltd. 微粉砕化有機化合物粒子の製造方法
WO2009026257A2 (en) * 2007-08-17 2009-02-26 Teva Pharmaceutical Industries Ltd. Methods and compositions for controlling the bioavailability of poorly soluble drugs
JP2009046438A (ja) * 2007-08-21 2009-03-05 Api Co Ltd アントシアニン含有組成物及びその製造方法

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018532769A (ja) * 2015-08-28 2018-11-08 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ウロリチン化合物を含む組成物
JP2018533618A (ja) * 2015-08-28 2018-11-15 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ウロリチン化合物を含む組成物
JP7161402B2 (ja) 2015-08-28 2022-10-26 アマゼンティス エスアー ウロリチン化合物を含む組成物
JP7227003B2 (ja) 2015-08-28 2023-02-21 アマゼンティス エスアー ウロリチン化合物を含む組成物
JP2025004129A (ja) * 2015-08-28 2025-01-14 アマゼンティス エスアー ウロリチン化合物を含む組成物
JP2023505128A (ja) * 2019-12-02 2023-02-08 アストラゼネカ・アクチエボラーグ ６－（２－クロロ－６－メチルピリジン－４－イル）－５－（４－フルオロフェニル）－１，２，４－トリアジン－３－アミンの固形製剤処方物
JP7731883B2 (ja) 2019-12-02 2025-09-01 アストラゼネカ・アクチエボラーグ ６－（２－クロロ－６－メチルピリジン－４－イル）－５－（４－フルオロフェニル）－１，２，４－トリアジン－３－アミンの固形製剤処方物
JP2024038209A (ja) * 2020-04-20 2024-03-19 ポビバ コーポレーション 抗ウイルス薬剤の向上した送達の為の組成物及び方法

Also Published As

Publication number Publication date
KR20130076818A (ko) 2013-07-08
RU2012149115A (ru) 2014-05-27
BR112012026843A2 (pt) 2016-07-12
EP2560617A2 (en) 2013-02-27
CN102985072A (zh) 2013-03-20
WO2011131943A2 (en) 2011-10-27
GT201200284A (es) 2014-08-26
WO2011131943A8 (en) 2012-11-29
US20130302415A1 (en) 2013-11-14
AU2011244783A1 (en) 2012-11-01
WO2011131943A3 (en) 2011-12-29
CA2796494A1 (en) 2011-10-27
ZA201207670B (en) 2013-05-29
NZ602955A (en) 2015-02-27
AU2011244783B2 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
AU2011244783B2 (en) Pharmaceutical compositions
JP2013538845A (ja) デフェラシロクスを含む医薬組成物
JP6351809B2 (ja) 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法
EP2442799B1 (en) Solid pharmaceutical composition comprising rivaroxaban
DK2421540T3 (en) Hitherto unknown formulation with meloxicam
US20080181959A1 (en) Solid composites of a calcium receptor-active compound
WO2015071668A1 (en) Pharmaceutical compositions
CN1886120A (zh) 用于制备可口腔给药的固态药物组合物的方法
JP2013537182A (ja) 医薬組成物
JP2025118693A (ja) エンザルタミドを含むナノ粒子
JP2018516942A (ja) 生体利用率が改善された含プランルカスト固形製剤の組成物及びその製造方法
KR102290670B1 (ko) 자가나노유화 약물전달시스템을 이용한 리바록사반의 경구용 고형제 조성물 및 이의 제조방법
US20070237828A1 (en) Ziprasidone Dosage Form
JP5900702B2 (ja) 経口投与用医薬組成物
MX2012012084A (es) Composicion farmaceutica.
CN102805745B (zh) 一种伊潘立酮组合物及其制备方法
OA16350A (en) Pharmaceutical composition comprising deferasirox.
OA16372A (en) Reclaimer machine.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140418

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150708

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160105